BioAge Labs (NASDAQ:BIOA) Announces Earnings Results

BioAge Labs (NASDAQ:BIOA) issued its quarterly earnings results on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11, Zacks reports.

BioAge Labs Price Performance

Shares of BIOA stock traded down $0.03 during trading hours on Thursday, reaching $7.47. 175,212 shares of the stock were exchanged, compared to its average volume of 276,870. The stock has a fifty day moving average price of $5.76. BioAge Labs has a 12-month low of $2.88 and a 12-month high of $22.92. The stock has a market cap of $267.80 million, a price-to-earnings ratio of -0.98 and a beta of 1.98.

Institutional Trading of BioAge Labs

Large investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after buying an additional 5,976 shares during the period. Walleye Capital LLC acquired a new position in BioAge Labs in the second quarter valued at approximately $64,000. Militia Capital Partners LP acquired a new position in BioAge Labs in the second quarter valued at approximately $166,000. Ameriprise Financial Inc. acquired a new position in BioAge Labs in the second quarter valued at approximately $182,000. Finally, Bridgeway Capital Management LLC acquired a new position in BioAge Labs in the second quarter valued at approximately $217,000.

Analysts Set New Price Targets

A number of brokerages have issued reports on BIOA. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. Citigroup boosted their price target on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $15.00.

BioAge Labs Company Profile

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.